Protein	B-GP
Phosphatase	I-GP
1	I-GP
Dephosphorylates	O
Profilin	B-GP
-	I-GP
1	I-GP
at	O
Ser	O
-	O
137	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
JS	O
MID	O
.	O

Performed	O
the	O
experiments	O
:	O
JS	O
.	O

Analyzed	O
the	O
data	O
:	O
JS	O
MID	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
JS	O
MID	O
.	O

Wrote	O
the	O
paper	O
:	O
JS	O
MID	O
.	O

Profilin	B-GP
-	I-GP
1	I-GP
(	O
PFN1	B-GP
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
actin	B-GP
dynamics	O
,	O
and	O
could	O
represent	O
an	O
important	O
therapeutic	O
target	O
in	O
several	O
diseases	O
.	O

We	O
previously	O
identified	O
PFN1	B-GP
as	O
a	O
huntingtin	B-GP
aggregation	O
inhibitor	O
,	O
and	O
others	O
have	O
implicated	O
it	O
as	O
a	O
tumor	B-DS
-	O
suppressor	O
.	O

Rho	B-GP
-	I-GP
associated	I-GP
kinase	I-GP
(	O
ROCK	B-GP
)	O
directly	O
phosphorylates	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
to	O
prevent	O
its	O
binding	O
to	O
polyproline	O
sequences	O
.	O

This	O
negatively	O
regulates	O
its	O
anti	O
-	O
aggregation	O
activity	O
.	O

However	O
,	O
the	O
phosphatase	B-GP
that	O
dephosphorylates	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
,	O
and	O
thus	O
activates	O
it	O
,	O
is	O
unknown	O
.	O

Using	O
a	O
phospho	O
-	O
specific	O
antibody	B-GP
against	O
Ser	O
-	O
137	O
of	O
PFN1	B-GP
,	O
we	O
characterized	O
PFN1	B-GP
dephosphorylation	O
in	O
cultured	O
cells	O
based	O
on	O
immunocytochemistry	O
and	O
a	O
quantitative	O
plate	O
reader	O
-	O
based	O
assay	O
.	O

Both	O
okadaic	O
acid	O
and	O
endothall	O
increased	O
pS137	O
-	O
PFN1	B-GP
levels	O
at	O
concentrations	O
more	O
consistent	O
with	O
their	O
known	O
IC50s	O
for	O
protein	B-GP
phosphatase	I-GP
1	I-GP
(	O
PP1	B-GP
)	O
than	O
protein	B-GP
phosphatase	I-GP
2A	I-GP
(	O
PP2A	B-GP
).	O

Knockdown	O
of	O
the	O
catalytic	O
subunit	O
of	O
PP1	B-GP
(	O
PP1Cα	B-GP
),	O
but	O
not	O
PP2A	B-GP
(	O
PP2ACα	B-GP
),	O
increased	O
pS137	O
-	O
PFN1	B-GP
levels	O
.	O

PP1Cα	B-GP
binds	O
PFN1	B-GP
in	O
cultured	O
cells	O
,	O
and	O
this	O
interaction	O
was	O
increased	O
by	O
a	O
phosphomimetic	O
mutation	O
of	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
(	O
S137D	O
).	O

Together	O
,	O
these	O
data	O
define	O
PP1	B-GP
as	O
the	O
principal	O
phosphatase	B-GP
for	O
Ser	O
-	O
137	O
of	O
PFN1	B-GP
,	O
and	O
provide	O
mechanistic	O
insights	O
into	O
PFN1	B-GP
regulation	O
by	O
phosphorylation	O
.	O

Introduction	O

Profilins	B-GP
are	O
small	O
actin	B-GP
-	I-GP
binding	I-GP
proteins	I-GP
that	O
are	O
essential	O
for	O
all	O
eukaryotic	O
cells	O
.	O

They	O
play	O
a	O
role	O
in	O
many	O
cellular	O
processes	O
including	O
cell	O
motility	O
,	O
cytokinesis	O
,	O
gene	O
transcription	O
,	O
endocytosis	O
and	O
neuronal	O
plasticity	O
[	O
1	O
],	O
[	O
2	O
],	O
[	O
3	O
],	O
[	O
4	O
].	O

These	O
activities	O
depend	O
on	O
their	O
interactions	O
with	O
three	O
major	O
cellular	O
ligands	O
:	O
globular	B-GP
actin	I-GP
(	O
G	B-GP
-	I-GP
actin	I-GP
),	O
polyproline	O
-	O
containing	O
proteins	O
,	O
and	O
phosphatidylinositols	O
(	O
e	O
.	O
g	O
.	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
,	O
PIP2	O
).	O

In	O
mammals	B-OG
,	O
four	O
profilin	B-GP
isoforms	O
have	O
been	O
identified	O
,	O
each	O
encoded	O
by	O
a	O
distinct	O
gene	O
.	O

Profilin	B-GP
-	I-GP
1	I-GP
(	O
PFN1	B-GP
)	O
and	O
profilin	B-GP
-	I-GP
2a	I-GP
(	O
PFN2a	B-GP
),	O
the	O
classic	O
“	O
somatic	O
”	O
isoforms	O
,	O
are	O
65	O
%	O
identical	O
in	O
amino	O
acid	O
sequence	O
,	O
and	O
highly	O
conserved	O
in	O
3D	O
structure	O
[	O
3	O
].	O

PFN1	B-GP
is	O
ubiquitously	O
expressed	O
,	O
while	O
PFN2a	B-GP
,	O
the	O
major	O
splice	O
isoform	O
of	O
PFN2	B-GP
,	O
is	O
preferentially	O
enriched	O
in	O
the	O
brain	O
[	O
3	O
].	O

Two	O
testis	O
-	O
specific	O
profilins	B-GP
,	O
PFN3	B-GP
and	O
PFN4	B-GP
,	O
are	O
recently	O
described	O
,	O
and	O
differ	O
substantially	O
from	O
PFN1	B-GP
and	O
PFN2a	B-GP
in	O
their	O
primary	O
sequences	O
[	O
5	O
].	O

Both	O
PFN3	B-GP
and	O
PFN4	B-GP
bind	O
G	B-GP
-	I-GP
actin	I-GP
with	O
lower	O
affinity	O
than	O
PFN1	B-GP
and	O
PFN2a	B-GP
.	O

PFN3	B-GP
binds	O
polyproline	O
-	O
ligands	O
poorly	O
,	O
and	O
PFN4	B-GP
completely	O
lacks	O
this	O
activity	O
[	O
5	O
].	O

Recent	O
studies	O
have	O
linked	O
profilins	B-GP
,	O
in	O
particular	O
PFN1	B-GP
,	O
to	O
several	O
human	B-OG
diseases	O
.	O

Our	O
prior	O
work	O
identified	O
PFN1	B-GP
as	O
an	O
inhibitor	O
of	O
huntingtin	B-GP
aggregation	O
,	O
suggesting	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
Huntington	B-DS
Disease	I-DS
(	O
HD	B-DS
).	O

The	O
anti	O
-	O
aggregation	O
activity	O
of	O
PFN1	B-GP
depends	O
on	O
its	O
binding	O
to	O
both	O
G	B-GP
-	I-GP
actin	I-GP
and	O
a	O
polyproline	O
tract	O
within	O
huntingtin	B-GP
[	O
6	O
].	O

PFN1	B-GP
is	O
also	O
a	O
putative	O
tumor	B-GP
suppressor	I-GP
,	O
and	O
has	O
been	O
shown	O
to	O
inhibit	O
tumor	B-DS
cell	O
growth	O
and	O
metastasis	O
in	O
several	O
cancer	B-DS
models	O
[	O
7	O
],	O
[	O
8	O
],	O
[	O
9	O
],	O
[	O
10	O
],	O
[	O
11	O
],	O
[	O
12	O
].	O

Despite	O
our	O
detailed	O
knowledge	O
of	O
profilin	B-GP
'	O
s	O
structure	O
and	O
functions	O
,	O
we	O
know	O
little	O
about	O
how	O
its	O
cellular	O
activities	O
are	O
regulated	O
.	O

PFN1	B-GP
is	O
a	O
phospho	B-GP
-	I-GP
protein	I-GP
in	O
vivo	O
[	O
13	O
],	O
[	O
14	O
],	O
suggesting	O
that	O
its	O
activities	O
could	O
be	O
regulated	O
by	O
phosphorylation	O
.	O

We	O
have	O
previously	O
determined	O
that	O
Ser	O
-	O
137	O
of	O
PFN1	B-GP
is	O
a	O
bona	O
fide	O
phosphorylation	O
site	O
for	O
the	O
Rho	B-GP
-	I-GP
associated	I-GP
kinase	I-GP
ROCK	B-GP
[	O
6	O
].	O

Ser	O
-	O
137	O
lies	O
within	O
the	O
polyproline	O
-	O
binding	O
site	O
of	O
PFN1	B-GP
.	O

Mimicking	O
phosphorylation	O
at	O
this	O
site	O
abolishes	O
PFN1	B-GP
'	O
s	O
binding	O
to	O
huntingtin	B-GP
,	O
and	O
inhibits	O
its	O
activity	O
as	O
an	O
aggregation	O
suppressor	O
[	O
6	O
].	O

To	O
our	O
knowledge	O
,	O
this	O
was	O
the	O
first	O
study	O
to	O
link	O
a	O
specific	O
phosphorylation	O
event	O
to	O
defined	O
cellular	O
functions	O
of	O
PFN1	B-GP
,	O
and	O
to	O
demonstrate	O
that	O
PFN1	B-GP
activity	O
is	O
regulated	O
.	O

While	O
our	O
prior	O
work	O
identified	O
ROCK	B-GP
as	O
an	O
upstream	O
kinase	B-GP
for	O
Ser	O
-	O
137	O
,	O
it	O
left	O
uncertain	O
which	O
phosphatase	B-GP
mediates	O
dephosphorylation	O
of	O
this	O
site	O
.	O

By	O
exploiting	O
a	O
highly	O
sensitive	O
and	O
specific	O
PFN1	B-GP
antibody	B-GP
against	O
pSer	O
-	O
137	O
,	O
we	O
now	O
provide	O
pharmacological	O
,	O
genetic	O
and	O
biochemical	O
evidence	O
that	O
protein	B-GP
phosphatase	I-GP
-	I-GP
1	I-GP
(	O
PP1	B-GP
)	O
exists	O
in	O
the	O
same	O
protein	O
complex	O
with	O
PFN1	B-GP
and	O
dephosphorylates	O
Ser	O
-	O
137	O
.	O

Results	O

P3490	O
specifically	O
recognizes	O
pS137	O
-	O
PFN1	B-GP
in	O
situ	O

We	O
previously	O
generated	O
a	O
polyclonal	O
phospho	O
-	O
specific	O
antibody	B-GP
against	O
pSer	O
-	O
137	O
of	O
PFN1	B-GP
(	O
P3490	O
).	O

Using	O
this	O
antibody	B-GP
,	O
we	O
previously	O
determined	O
by	O
Western	O
blot	O
(	O
WB	O
)	O
that	O
pS137	O
-	O
PFN1	B-GP
levels	O
in	O
cultured	O
cells	O
are	O
regulated	O
by	O
RhoA	B-GP
/	O
ROCK	B-GP
signaling	O
.	O

The	O
RhoA	B-GP
activator	O
lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
mildly	O
increased	O
pS137	O
-	O
PFN1	B-GP
levels	O
in	O
cultured	O
cells	O
,	O
which	O
was	O
blocked	O
by	O
the	O
ROCK	B-GP
inhibitor	O
Y	O
-	O
27632	O
[	O
6	O
].	O

To	O
directly	O
characterize	O
the	O
phospho	O
-	O
specificity	O
of	O
this	O
antibody	B-GP
,	O
we	O
pre	O
-	O
incubated	O
P3490	O
with	O
antigenic	O
peptides	O
containing	O
(	O
pS137	O
)	O
or	O
lacking	O
a	O
phosphate	O
on	O
Ser	O
-	O
137	O
(	O
S137	O
),	O
followed	O
by	O
WB	O
to	O
determine	O
if	O
its	O
reactivity	O
with	O
cellular	O
PFN1	B-GP
was	O
affected	O
.	O

The	O
pS137	O
-	O
peptide	O
completely	O
blocked	O
P3490	O
binding	O
to	O
PFN1	B-GP
(	O
Fig	O
.	O
1A	O
)	O
as	O
expected	O
.	O

However	O
,	O
the	O
non	O
-	O
phospho	O
S137	O
-	O
peptide	O
effectively	O
blocked	O
90	O
%	O
of	O
the	O
PFN1	B-GP
signal	O
versus	O
the	O
no	O
peptide	O
control	O
(	O
Fig	O
.	O
1A	O
).	O

Thus	O
,	O
P3490	O
contains	O
pan	O
-	O
antibodies	B-GP
that	O
react	O
with	O
unphosphorylated	O
PFN1	B-GP
,	O
and	O
the	O
bulk	O
of	O
the	O
observed	O
PFN1	B-GP
signal	O
likely	O
represents	O
cross	O
-	O
reactivity	O
with	O
unphosphorylated	O
PFN1	B-GP
molecules	O
that	O
outnumber	O
those	O
of	O
phospho	O
-	O
PFN1	B-GP
.	O

This	O
limits	O
the	O
fidelity	O
of	O
P3490	O
to	O
accurately	O
report	O
pS137	O
-	O
PFN1	B-GP
levels	O
via	O
WB	O
.	O

In	O
situ	O
staining	O
of	O
mammalian	O
cells	O
by	O
pSer	O
-	O
137	O
-	O
PFN1	B-GP
antibody	B-GP
P3490	O
is	O
responsive	O
to	O
RhoA	B-GP
/	O
ROCK	B-GP
signaling	O
.	O

A	O
,	O
Equal	O
amounts	O
of	O
HEK293	O
cell	O
lysate	O
were	O
separated	O
on	O
SDS	O
-	O
PAGE	O
,	O
and	O
individual	O
lanes	O
were	O
blotted	O
with	O
P3490	O
that	O
was	O
pre	O
-	O
incubated	O
with	O
no	O
peptide	O
(	O
Lane	O
1	O
),	O
or	O
PFN1	B-GP
peptides	O
containing	O
unphosphorylated	O
(	O
Lane	O
2	O
)	O
or	O
phosphorylated	O
Ser	O
-	O
137	O
(	O
Lane	O
3	O
).	O

PFN1	B-GP
-	O
pS137	O
peptide	O
completely	O
blocked	O
the	O
binding	O
of	O
P3490	O
to	O
PFN1	B-GP
.	O

Unphosphorylated	O
PFN1	B-GP
-	O
S137	O
peptide	O
blocked	O
∼	O
90	O
%	O
binding	O
vs	O
.	O
the	O
no	O
peptide	O
control	O
.	O

Total	O
PFN1	B-GP
(	O
on	O
a	O
separate	O
and	O
identically	O
loaded	O
gel	O
)	O
and	O
actin	B-GP
levels	O
were	O
confirmed	O
as	O
being	O
equal	O
across	O
all	O
lanes	O
.	O
B	O
,	O
P3490	O
stains	O
the	O
cytoplasm	O
of	O
multiple	O
cell	O
lines	O
in	O
a	O
heterogeneous	O
fashion	O
,	O
including	O
HEK293	O
,	O
HeLa	O
and	O
NIH	O
3T3	O
(	O
in	O
green	O
).	O

DAPI	O
was	O
used	O
as	O
counterstain	O
(	O
in	O
blue	O
).	O
C	O
,	O
Immunostaining	O
of	O
HEK293	O
cells	O
with	O
P3490	O
(	O
green	O
)	O
was	O
unaffected	O
by	O
pre	O
-	O
incubation	O
with	O
the	O
unphosphorylated	O
PFN1	B-GP
-	O
S137	O
peptide	O
,	O
but	O
was	O
completely	O
inhibited	O
by	O
the	O
phosphorylated	O
PFN1	B-GP
-	O
pS137	O
peptide	O
.	O

DAPI	O
staining	O
is	O
shown	O
in	O
blue	O
.	O
D	O
,	O
NIH	O
3T3	O
cells	O
were	O
serum	O
-	O
starved	O
for	O
16	O
hr	O
in	O
the	O
absence	O
or	O
presence	O
of	O
50	O
µM	O
Y	O
-	O
27632	O
,	O
followed	O
by	O
treatment	O
with	O
10	O
µM	O
Lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
for	O
60	O
min	O
.	O

Cells	O
were	O
immunostained	O
with	O
P3490	O
(	O
green	O
)	O
and	O
counterstained	O
with	O
DAPI	O
(	O
blue	O
)	O
(	O
a	O
–	O
c	O
).	O

LPA	O
increased	O
P3490	O
staining	O
,	O
which	O
was	O
blocked	O
by	O
the	O
pretreatment	O
with	O
Y	O
-	O
27632	O
.	O

Total	O
PFN1	B-GP
levels	O
were	O
unaffected	O
by	O
these	O
treatments	O
as	O
indicated	O
by	O
immunostaining	O
with	O
a	O
generic	O
PFN1	B-GP
antibody	B-GP
(	O
PFN1	B-GP
in	O
green	O
and	O
DAPI	O
in	O
blue	O
)	O
(	O
d	O
–	O
l	O
).	O
E	O
,	O
HEK293	O
cells	O
were	O
treated	O
with	O
or	O
without	O
50	O
µM	O
hydroxyfasudil	O
(	O
OH	O
-	O
fasudil	O
)	O
for	O
2	O
hr	O
,	O
followed	O
by	O
immunostaining	O
with	O
P3490	O
(	O
a	O
–	O
b	O
)	O
or	O
the	O
generic	O
PFN1	B-GP
antibody	B-GP
(	O
c	O
–	O
d	O
)	O
(	O
both	O
in	O
green	O
)	O
and	O
counterstaining	O
with	O
DAPI	O
(	O
blue	O
).	O

Nearly	O
all	O
cells	O
treated	O
with	O
OH	O
-	O
fasudil	O
became	O
P3490	O
-	O
negative	O
without	O
changes	O
in	O
their	O
total	O
PFN1	B-GP
levels	O
.	O
F	O
,	O
HEK293	O
cells	O
grown	O
in	O
a	O
96	O
-	O
well	O
plate	O
were	O
treated	O
for	O
24	O
hr	O
with	O
increasing	O
concentrations	O
of	O
OH	O
-	O
fasudil	O
(	O
1	O
,	O
3	O
,	O
10	O
,	O
50	O
µM	O
),	O
immunostained	O
with	O
P3490	O
and	O
Alexa	O
Fluor	O
®	O
488	O
-	O
labeled	O
secondary	O
antibody	B-GP
,	O
and	O
counterstained	O
with	O
DAPI	O
.	O

Fluorescence	O
intensity	O
was	O
quantified	O
on	O
a	O
fluorescence	O
plate	O
reader	O
.	O

P3490	O
staining	O
was	O
normalized	O
vs	O
.	O
DAPI	O
to	O
control	O
for	O
cell	O
numbers	O
,	O
and	O
the	O
effects	O
of	O
OH	O
-	O
fasudil	O
were	O
calculated	O
as	O
relative	O
values	O
as	O
compared	O
to	O
the	O
untreated	O
cells	O
.	O

OH	O
-	O
fasudil	O
reduced	O
P3490	O
staining	O
dose	O
-	O
dependently	O
.	O

Error	O
bars	O
represent	O
the	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
of	O
three	O
independent	O
experiments	O
.	O

Due	O
to	O
the	O
limitation	O
of	O
P3490	O
associated	O
with	O
WB	O
,	O
we	O
tested	O
if	O
it	O
can	O
detect	O
pS137	O
-	O
PFN1	B-GP
in	O
situ	O
by	O
immunocytochemistry	O
.	O

P3490	O
heterogeneously	O
stained	O
several	O
cell	O
lines	O
(	O
predominantly	O
the	O
cytoplasm	O
),	O
i	O
.	O
e	O
.	O
not	O
all	O
cells	O
were	O
positive	O
at	O
the	O
same	O
time	O
(	O
Fig	O
.	O
1B	O
).	O

The	O
cause	O
for	O
this	O
staining	O
pattern	O
of	O
P3490	O
is	O
unclear	O
,	O
but	O
could	O
either	O
reflect	O
individual	O
variation	O
among	O
cells	O
,	O
or	O
cell	O
cycle	O
dependence	O
.	O

Cell	O
staining	O
by	O
P3490	O
was	O
completely	O
inhibited	O
by	O
its	O
pre	O
-	O
incubation	O
with	O
the	O
pS137	O
-	O
peptide	O
,	O
but	O
was	O
unaffected	O
by	O
the	O
unphosphorylated	O
S137	O
-	O
peptide	O
(	O
Fig	O
.	O
1C	O
).	O

This	O
contrasted	O
the	O
results	O
on	O
WB	O
,	O
and	O
suggested	O
that	O
P3490	O
is	O
highly	O
phospho	O
-	O
specific	O
when	O
used	O
for	O
in	O
situ	O
cell	O
staining	O
,	O
in	O
which	O
the	O
pan	O
-	O
antibodies	B-GP
are	O
nonreactive	O
.	O

In	O
serum	O
-	O
starved	O
NIH	O
3T3	O
cells	O
,	O
the	O
RhoA	B-GP
activator	O
lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
markedly	O
increased	O
the	O
number	O
of	O
P3490	O
-	O
positive	O
cells	O
,	O
and	O
this	O
was	O
blocked	O
by	O
ROCK	B-GP
inhibition	O
with	O
Y	O
-	O
27632	O
(	O
Fig	O
.	O
1D	O
).	O

Hydroxyfasudil	O
(	O
OH	O
-	O
fasudil	O
),	O
a	O
ROCK	B-GP
inhibitor	O
structurally	O
distinct	O
from	O
Y	O
-	O
27632	O
,	O
also	O
dose	O
-	O
dependently	O
reduced	O
P3490	O
staining	O
.	O

These	O
effects	O
were	O
visible	O
microscopically	O
(	O
Fig	O
.	O
1E	O
),	O
and	O
easily	O
quantified	O
using	O
a	O
fluorescence	O
plate	O
reader	O
following	O
incubation	O
with	O
a	O
fluorescently	O
-	O
labeled	O
(	O
Alexa	O
Fluor	O
®	O
488	O
)	O
secondary	O
antibody	B-GP
(	O
Fig	O
.	O
1F	O
).	O

At	O
50	O
µM	O
,	O
OH	O
-	O
fasudil	O
eliminated	O
P3490	O
staining	O
in	O
nearly	O
all	O
cells	O
without	O
affecting	O
their	O
total	O
PFN1	B-GP
levels	O
(	O
Fig	O
.	O
1E	O
).	O

We	O
further	O
confirmed	O
the	O
specificity	O
of	O
P3490	O
for	O
pS137	O
-	O
PFN1	B-GP
using	O
RNAi	O
knockdown	O
of	O
endogenous	O
PFN1	B-GP
.	O

HEK293	O
cells	O
were	O
transduced	O
with	O
lentiviral	O
shRNAs	O
targeting	O
PFN1	B-GP
(	O
Fig	O
.	O
2A	O
),	O
which	O
reduced	O
P3490	O
staining	O
(	O
Fig	O
.	O
2B	O
–	O
C	O
),	O
consistent	O
with	O
PFN1	B-GP
being	O
the	O
cellular	O
target	O
of	O
the	O
antibody	B-GP
.	O

This	O
effect	O
was	O
evident	O
microscopically	O
(	O
Fig	O
.	O
2B	O
),	O
and	O
was	O
quantified	O
using	O
the	O
fluorescence	O
plate	O
reader	O
(	O
Fig	O
.	O
2C	O
).	O

The	O
relative	O
decrease	O
in	O
total	O
PFN1	B-GP
level	O
(	O
60	O
%)	O
as	O
a	O
result	O
of	O
shRNA	O
knockdown	O
was	O
larger	O
than	O
that	O
of	O
P3490	O
staining	O
(	O
40	O
%).	O

This	O
implies	O
that	O
Ser	O
-	O
137	O
phosphorylation	O
of	O
PFN1	B-GP
may	O
need	O
to	O
be	O
kept	O
at	O
a	O
certain	O
level	O
in	O
the	O
cell	O
,	O
and	O
could	O
be	O
regulated	O
in	O
a	O
fashion	O
partially	O
independent	O
of	O
total	O
PFN1	B-GP
levels	O
.	O

In	O
addition	O
,	O
P3490	O
stained	O
ectopically	O
expressed	O
phosphomimetic	O
PFN1	B-GP
(	O
S137D	O
)	O
in	O
cultured	O
cells	O
,	O
but	O
not	O
PFN1	B-GP
(	O
wt	O
)	O
or	O
PFN1	B-GP
(	O
S137A	O
).	O

This	O
was	O
most	O
evident	O
when	O
phosphorylation	O
of	O
endogenous	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
was	O
inhibited	O
by	O
OH	O
-	O
fasudil	O
(	O
Fig	O
.	O
2D	O
),	O
and	O
was	O
also	O
quantified	O
by	O
the	O
fluorescence	O
plate	O
reader	O
(	O
Fig	O
.	O
2E	O
and	O
F	O
).	O

Taken	O
together	O
,	O
these	O
results	O
confirmed	O
the	O
specificity	O
of	O
P3490	O
for	O
pS137	O
-	O
PFN1	B-GP
for	O
in	O
situ	O
staining	O
.	O

P3490	O
specifically	O
detects	O
pS137	O
-	O
PFN1	B-GP
via	O
immunofluorescence	O
staining	O
.	O

A	O
,	O
HEK293	O
cells	O
were	O
infected	O
for	O
three	O
days	O
with	O
lentiviral	O
shRNA	O
particles	O
encoding	O
either	O
a	O
scrambled	O
nucleotide	O
sequence	O
(	O
Ctrl	O
shRNA	O
),	O
or	O
a	O
target	O
-	O
specific	O
sequence	O
for	O
human	B-OG
PFN1	B-GP
(	O
PFN1	B-GP
shRNA	O
).	O

Efficient	O
PFN1	B-GP
knockdown	O
was	O
confirmed	O
by	O
Western	O
blot	O
.	O
B	O
,	O
virus	B-OG
-	O
mediated	O
PFN1	B-GP
knockdown	O
reduced	O
P3490	O
staining	O
(	O
green	O
,	O
a	O
–	O
b	O
),	O
as	O
visualized	O
by	O
confocal	O
fluorescence	O
microscope	O
.	O

Total	O
PFN1	B-GP
decrease	O
was	O
also	O
confirmed	O
by	O
immunofluorescence	O
staining	O
(	O
green	O
,	O
c	O
–	O
d	O
).	O

DAPI	O
(	O
blue	O
)	O
was	O
used	O
to	O
counterstain	O
cells	O
either	O
as	O
merged	O
(	O
a	O
–	O
b	O
)	O
or	O
unmerged	O
images	O
(	O
e	O
–	O
f	O
).	O
C	O
,	O
staining	O
of	O
virus	B-OG
-	O
infected	O
cells	O
with	O
P3490	O
and	O
PFN1	B-GP
antibodies	B-GP
(	O
as	O
in	O
A	O
and	O
B	O
)	O
was	O
quantified	O
by	O
fluorescence	O
plate	O
reader	O
,	O
and	O
normalized	O
vs	O
.	O
DAPI	O
to	O
control	O
for	O
cell	O
numbers	O
.	O

The	O
decrease	O
of	O
P3490	O
(∼	O
40	O
%;	O
*,	O
p	O
<	O
0	O
.	O
05	O
,	O
unpaired	O
t	O
-	O
test	O
)	O
and	O
total	O
PFN1	B-GP
(	O
60	O
%;	O
p	O
<	O
0	O
.	O
001	O
,	O
unpaired	O
t	O
-	O
test	O
)	O
staining	O
caused	O
by	O
PFN1	B-GP
knockdown	O
was	O
calculated	O
relative	O
to	O
cells	O
infected	O
with	O
the	O
control	O
shRNA	O
(	O
arbitrarily	O
set	O
as	O
1	O
).	O

Error	O
bars	O
represent	O
the	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
of	O
three	O
independent	O
experiments	O
.	O
D	O
,	O
HEK293	O
cells	O
were	O
transiently	O
transfected	O
with	O
Myc	B-GP
-	O
tagged	O
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
or	O
S137D	O
),	O
treated	O
with	O
50	O
µM	O
hydroxyfasudil	O
for	O
16	O
hr	O
,	O
and	O
double	O
stained	O
with	O
an	O
anti	O
-	O
Myc	B-GP
(	O
red	O
)	O
and	O
P3490	O
(	O
green	O
)	O
antibodies	B-GP
.	O

Only	O
cells	O
expressing	O
the	O
phosphomimetic	O
Myc	B-GP
-	O
PFN1	B-GP
(	O
S137D	O
)	O
stained	O
positive	O
with	O
P3490	O
(	O
g	O
–	O
i	O
),	O
but	O
not	O
Myc	B-GP
-	O
PFN1	B-GP
(	O
wt	O
)	O
(	O
a	O
–	O
c	O
)	O
or	O
Myc	B-GP
-	O
PFN1	B-GP
(	O
S137A	O
)	O
(	O
d	O
–	O
f	O
).	O

Arrowheads	O
indicate	O
two	O
cells	O
that	O
expressed	O
Myc	B-GP
-	O
PFN1	B-GP
(	O
S137D	O
)	O
and	O
stained	O
positive	O
with	O
P3490	O
.	O
E	O
,	O
Western	O
blot	O
confirmed	O
comparable	O
levels	O
of	O
Myc	B-GP
-	O
PFN1	B-GP
over	O
-	O
expression	O
(	O
wt	O
,	O
S137A	O
and	O
S137D	O
)	O
in	O
transiently	O
transfected	O
HEK293	O
cells	O
,	O
as	O
compared	O
to	O
cells	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pcDNA3	O
).	O
F	O
,	O
cells	O
transfected	O
(	O
as	O
in	O
E	O
)	O
with	O
pcDNA3	O
or	O
various	O
PFN1	B-GP
constructs	O
were	O
immunostained	O
with	O
P3490	O
,	O
and	O
quantified	O
on	O
a	O
fluorescence	O
plate	O
reader	O
with	O
normalization	O
vs	O
.	O
DAPI	O
.	O

The	O
effects	O
of	O
PFN1	B-GP
over	O
-	O
expression	O
on	O
P3490	O
staining	O
are	O
represented	O
as	O
relative	O
change	O
compared	O
to	O
cells	O
transfected	O
with	O
pcDNA3	O
.	O

Only	O
PFN1	B-GP
(	O
S137D	O
)	O
increased	O
P3490	O
staining	O
(***,	O
p	O
<	O
0	O
.	O
001	O
,	O
unpaired	O
t	O
-	O
test	O
).	O

Cells	O
were	O
not	O
treated	O
with	O
hydroxyfasudil	O
.	O

Error	O
bars	O
represent	O
the	O
SEM	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
of	O
three	O
independent	O
experiments	O
.	O

Phosphatase	B-GP
inhibitors	O
increase	O
pS137	O
-	O
PFN1	B-GP
levels	O
in	O
cultured	O
cells	O

To	O
identify	O
candidate	O
phosphatases	B-GP
for	O
pSer	O
-	O
137	O
of	O
PFN1	B-GP
,	O
we	O
employed	O
pharmacologic	O
inhibitors	O
of	O
serine	B-GP
/	I-GP
threonine	I-GP
phosphatases	I-GP
in	O
cultured	O
cells	O
.	O

Okadaic	O
acid	O
(	O
OA	O
)	O
inhibits	O
the	O
serine	B-GP
/	I-GP
threonine	I-GP
-	I-GP
specific	I-GP
phosphoprotein	I-GP
phosphatase	I-GP
(	O
PPP	B-GP
)	O
family	O
,	O
in	O
particular	O
its	O
two	O
most	O
abundant	O
members	O
,	O
PP1	B-GP
and	O
PP2A	B-GP
[	O
15	O
].	O

Differential	O
potencies	O
of	O
OA	O
towards	O
its	O
target	O
phosphatases	B-GP
have	O
enabled	O
its	O
use	O
to	O
implicate	O
candidates	O
,	O
particularly	O
PP1	B-GP
(	O
IC50	O
∼	O
15	O
–	O
50	O
nM	O
)	O
and	O
PP2A	B-GP
(	O
IC50	O
∼	O
0	O
.	O
1	O
–	O
0	O
.	O
3	O
nM	O
)	O
[	O
16	O
].	O

Thus	O
,	O
we	O
treated	O
HEK293	O
cells	O
with	O
increasing	O
concentrations	O
of	O
OA	O
,	O
and	O
tested	O
the	O
effects	O
on	O
pS137	O
-	O
PFN1	B-GP
levels	O
by	O
immunostaining	O
with	O
P3490	O
.	O

16	O
hr	O
of	O
OA	O
treatment	O
markedly	O
increased	O
the	O
number	O
of	O
P3490	O
-	O
positive	O
cells	O
at	O
mid	O
-	O
nanomolar	O
concentrations	O
(≥	O
10	O
nM	O
),	O
which	O
was	O
evident	O
both	O
microscopically	O
(	O
Fig	O
.	O
3A	O
)	O
and	O
after	O
quantification	O
using	O
a	O
fluorescence	O
plate	O
reader	O
(	O
Fig	O
.	O
3B	O
).	O

The	O
effective	O
concentration	O
of	O
OA	O
to	O
increase	O
pS137	O
-	O
PFN1	B-GP
levels	O
was	O
much	O
higher	O
than	O
its	O
IC50	O
for	O
PP2A	B-GP
(	O
0	O
.	O
1	O
–	O
0	O
.	O
3	O
nM	O
),	O
and	O
more	O
consistent	O
with	O
its	O
known	O
IC50	O
for	O
PP1	B-GP
(	O
15	O
–	O
50	O
nM	O
).	O

We	O
also	O
used	O
endothall	O
,	O
a	O
structurally	O
distinct	O
phosphatase	B-GP
inhibitor	O
that	O
is	O
also	O
much	O
more	O
potent	O
against	O
PP2A	B-GP
(	O
IC50	O
=	O
90	O
nM	O
)	O
than	O
PP1	B-GP
(	O
IC50	O
=	O
5	O
µM	O
)	O
[	O
17	O
],	O
[	O
18	O
].	O

Like	O
OA	O
,	O
endothall	O
increased	O
P3490	O
staining	O
at	O
concentrations	O
(	O
mid	O
-	O
micromolar	O
)	O
that	O
are	O
substantially	O
higher	O
than	O
its	O
IC50	O
for	O
PP2A	B-GP
,	O
but	O
similar	O
to	O
that	O
for	O
PP1	B-GP
(	O
Fig	O
.	O
3A	O
and	O
3B	O
).	O

Due	O
to	O
cytotoxic	O
effects	O
at	O
high	O
concentrations	O
,	O
we	O
were	O
unable	O
to	O
carry	O
out	O
complete	O
dose	O
-	O
responses	O
of	O
OA	O
and	O
endothall	O
with	O
regard	O
to	O
pS137	O
-	O
PFN1	B-GP
levels	O
.	O

At	O
their	O
effective	O
concentrations	O
,	O
neither	O
drug	O
affected	O
the	O
total	O
PFN1	B-GP
levels	O
within	O
cells	O
(	O
Fig	O
.	O
3C	O
).	O

Fostriecin	O
,	O
a	O
highly	O
specific	O
and	O
potent	O
inhibitor	O
of	O
PP2A	B-GP
(	O
IC50	O
for	O
PP2A	B-GP
=	O
1	O
.	O
5	O
–	O
5	O
.	O
5	O
nM	O
;	O
IC50	O
for	O
PP1	B-GP
=	O
45	O
–	O
58	O
µM	O
),	O
had	O
no	O
effect	O
on	O
P3490	O
staining	O
,	O
even	O
at	O
1	O
µM	O
(	O
data	O
not	O
shown	O
),	O
a	O
concentration	O
expected	O
to	O
fully	O
inhibit	O
PP2A	B-GP
in	O
a	O
living	O
cell	O
[	O
16	O
].	O

Taken	O
together	O
,	O
these	O
results	O
suggested	O
that	O
PP1	B-GP
,	O
rather	O
than	O
PP2A	B-GP
,	O
might	O
be	O
responsible	O
for	O
dephosphorylation	O
of	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
.	O

Pharmacologic	O
inhibition	O
of	O
serine	B-GP
/	I-GP
threonine	I-GP
phosphatases	I-GP
increases	O
pS137	O
-	O
PFN1	B-GP
in	O
cultured	O
cells	O
.	O

A	O
,	O
HEK293	O
cells	O
were	O
treated	O
with	O
okadaic	O
acid	O
(	O
OA	O
)	O
(	O
a	O
–	O
d	O
)	O
or	O
endothall	O
(	O
e	O
–	O
h	O
)	O
for	O
16	O
hr	O
at	O
increasing	O
concentrations	O
(	O
1	O
,	O
3	O
and	O
10	O
nM	O
for	O
OA	O
;	O
1	O
,	O
3	O
and	O
10	O
µM	O
for	O
endothall	O
),	O
followed	O
by	O
immunostaining	O
with	O
P3490	O
(	O
green	O
)	O
and	O
counterstaining	O
with	O
DAPI	O
(	O
blue	O
).	O

The	O
number	O
of	O
P3490	O
-	O
positive	O
cells	O
and	O
overall	O
P3490	O
staining	O
intensity	O
increased	O
notably	O
at	O
10	O
nM	O
of	O
OA	O
and	O
10	O
µM	O
of	O
endothall	O
treatment	O
.	O
B	O
,	O
effects	O
of	O
OA	O
and	O
endothall	O
on	O
P3490	O
staining	O
were	O
quantified	O
using	O
a	O
fluorescence	O
plate	O
reader	O
.	O

P3490	O
levels	O
were	O
normalized	O
vs	O
.	O
DAPI	O
,	O
and	O
the	O
effects	O
of	O
the	O
drugs	O
were	O
represented	O
as	O
relative	O
change	O
vs	O
.	O
the	O
vehicle	O
controls	O
.	O

OA	O
and	O
endothall	O
increased	O
P3490	O
staining	O
dose	O
-	O
dependently	O
.	O

Error	O
bars	O
represent	O
the	O
SEM	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
of	O
three	O
independent	O
experiments	O
.	O
C	O
,	O
HEK293	O
cells	O
treated	O
with	O
10	O
nM	O
OA	O
(	O
a	O
–	O
b	O
)	O
or	O
10	O
µM	O
endothall	O
(	O
c	O
–	O
d	O
)	O
were	O
immunostained	O
for	O
total	O
PFN1	B-GP
(	O
green	O
)	O
and	O
counterstained	O
with	O
DAPI	O
(	O
blue	O
).	O

Merged	O
images	O
showed	O
no	O
changes	O
in	O
total	O
PFN1	B-GP
levels	O
as	O
a	O
result	O
of	O
the	O
drugs	O
.	O

Genetic	O
modulation	O
of	O
PP1	B-GP
activity	O
controls	O
pS137	O
-	O
PFN1	B-GP
levels	O
in	O
cultured	O
cells	O

The	O
above	O
effects	O
of	O
phosphatase	B-GP
inhibitors	O
indicated	O
a	O
role	O
of	O
PP1	B-GP
in	O
pS137	O
-	O
PFN1	B-GP
dephosphorylation	O
.	O

To	O
test	O
this	O
more	O
definitively	O
,	O
we	O
knocked	O
down	O
the	O
alpha	O
isoform	O
of	O
the	O
PP1	B-GP
catalytic	O
subunit	O
,	O
PP1Cα	B-GP
,	O
by	O
transfecting	O
HEK293	O
cells	O
with	O
siRNAs	O
.	O

In	O
parallel	O
,	O
we	O
also	O
knocked	O
down	O
the	O
alpha	O
isoform	O
of	O
the	O
PP2A	B-GP
catalytic	O
subunit	O
,	O
PP2ACα	B-GP
.	O

Based	O
on	O
Western	O
blot	O
analysis	O
,	O
endogenous	O
PP1Cα	B-GP
and	O
PP2ACα	B-GP
were	O
both	O
knocked	O
down	O
by	O
90	O
%	O
with	O
no	O
effect	O
on	O
cellular	O
PFN1	B-GP
levels	O
(	O
Fig	O
.	O
4C	O
).	O

This	O
was	O
also	O
confirmed	O
via	O
immunofluorescence	O
staining	O
of	O
the	O
transfected	O
cells	O
(	O
Fig	O
.	O
4A	O
).	O

We	O
detected	O
a	O
three	O
-	O
fold	O
increase	O
of	O
P3490	O
staining	O
in	O
cells	O
transfected	O
with	O
the	O
PP1Cα	B-GP
-	O
specific	O
siRNA	O
in	O
comparison	O
to	O
those	O
transfected	O
with	O
the	O
control	O
siRNA	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
).	O

In	O
contrast	O
,	O
silencing	O
PP2ACα	B-GP
had	O
no	O
effect	O
on	O
P3490	O
staining	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
).	O

As	O
an	O
additional	O
test	O
,	O
in	O
HeLa	O
cells	O
we	O
over	O
-	O
expressed	O
wild	O
-	O
type	O
PP1Cα	B-GP
,	O
a	O
catalytically	O
inactive	O
PP1Cα	B-GP
(	O
H125A	O
)	O
mutant	O
,	O
or	O
wild	O
-	O
type	O
PP2ACα	B-GP
,	O
and	O
stained	O
with	O
P3490	O
.	O

Nearly	O
all	O
cells	O
expressing	O
wild	O
type	O
PP1Cα	B-GP
stained	O
negative	O
for	O
pS137	O
-	O
PFN1	B-GP
,	O
while	O
many	O
cells	O
expressing	O
the	O
inactive	O
PP1Cα	B-GP
(	O
H125A	O
)	O
mutant	O
or	O
wild	O
type	O
PP2ACα	B-GP
stained	O
positive	O
for	O
pS137	O
-	O
PFN1	B-GP
(	O
Fig	O
.	O
4D	O
).	O

These	O
data	O
strongly	O
suggested	O
that	O
PP1	B-GP
dephosphorylates	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
.	O

Protein	B-GP
phosphatase	I-GP
-	I-GP
1	I-GP
(	O
PP1	B-GP
)	O
dephosphorylates	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
.	O

A	O
,	O
HEK293	O
cells	O
were	O
transfected	O
with	O
control	O
,	O
or	O
sequence	O
-	O
specific	O
siRNAs	O
targeting	O
human	B-OG
PP1Cα	B-GP
or	O
PP2ACα	B-GP
.	O

They	O
were	O
immunostained	O
with	O
P3490	O
(	O
a	O
–	O
c	O
)	O
or	O
the	O
antibody	B-GP
against	O
total	O
PFN1	B-GP
(	O
d	O
–	O
f	O
)	O
(	O
both	O
in	O
green	O
)	O
and	O
counterstained	O
with	O
DAPI	O
(	O
blue	O
).	O

Silencing	O
PP1Cα	B-GP
,	O
but	O
not	O
PP2ACα	B-GP
,	O
increased	O
the	O
number	O
of	O
P3490	O
-	O
positive	O
cells	O
and	O
their	O
staining	O
intensities	O
,	O
while	O
having	O
no	O
effect	O
on	O
total	O
PFN1	B-GP
levels	O
.	O
B	O
,	O
effects	O
of	O
PP1Cα	B-GP
and	O
PP2ACα	B-GP
knockdown	O
on	O
P3490	O
staining	O
were	O
quantified	O
using	O
the	O
fluorescence	O
plate	O
reader	O
,	O
normalized	O
vs	O
.	O
DAPI	O
,	O
and	O
represented	O
as	O
change	O
relative	O
to	O
control	O
siRNA	O
.	O

PP1Cα	B-GP
knockdown	O
increased	O
P3490	O
staining	O
three	O
-	O
fold	O
(***,	O
p	O
<	O
0	O
.	O
001	O
,	O
unpaired	O
t	O
-	O
test	O
),	O
while	O
PP2ACα	B-GP
knockdown	O
had	O
no	O
effect	O
.	O

Error	O
bars	O
represent	O
the	O
SEM	O
.	O

Data	O
are	O
mean	O
±	O
S	O
.	O
E	O
.	O
M	O
.	O
of	O
three	O
independent	O
experiments	O
.	O
C	O
,	O
Western	O
blot	O
confirmed	O
>	O
90	O
%	O
knockdown	O
of	O
both	O
PP1Cα	B-GP
and	O
PP2ACα	B-GP
in	O
HEK293	O
cells	O
.	O

Neither	O
affected	O
PFN1	B-GP
levels	O
.	O

Arrowhead	O
indicates	O
PP1Cα	B-GP
.	O

The	O
identity	O
of	O
the	O
protein	O
band	O
above	O
PP1Cα	B-GP
,	O
which	O
cross	O
-	O
reacts	O
with	O
PP1Cα	B-GP
antibody	B-GP
,	O
is	O
unknown	O
.	O
D	O
,	O
HeLa	O
cells	O
were	O
transfected	O
with	O
Myc	B-GP
-	O
PP1Cα	B-GP
(	O
wt	O
)	O
(	O
a	O
–	O
c	O
),	O
Myc	B-GP
-	O
PP1Cα	B-GP
(	O
H125A	O
)	O
(	O
catalytically	O
inactive	O
)	O
(	O
d	O
–	O
f	O
)	O
or	O
Myc	B-GP
-	O
PP2ACα	B-GP
(	O
g	O
–	O
i	O
),	O
double	O
immunolabeled	O
with	O
an	O
anti	O
-	O
Myc	B-GP
antibody	B-GP
(	O
red	O
)	O
and	O
P3490	O
(	O
green	O
),	O
and	O
counterstained	O
with	O
DAPI	O
(	O
blue	O
).	O

Neither	O
Myc	B-GP
-	O
PP1Cα	B-GP
(	O
H125A	O
)	O
nor	O
Myc	B-GP
-	O
PP2ACα	B-GP
over	O
-	O
expression	O
affected	O
P3490	O
staining	O
of	O
the	O
transfected	O
cells	O
(	O
as	O
indicated	O
by	O
the	O
presence	O
of	O
cells	O
that	O
were	O
both	O
red	O
and	O
green	O
).	O

However	O
,	O
PP1Cα	B-GP
(	O
wt	O
)	O
over	O
-	O
expression	O
inhibited	O
P3490	O
staining	O
(	O
as	O
indicated	O
by	O
the	O
mutual	O
exclusivity	O
of	O
red	O
and	O
green	O
cells	O
).	O

PP1	B-GP
interacts	O
with	O
PFN1	B-GP
in	O
a	O
pS137	O
-	O
dependent	O
manner	O

The	O
preceding	O
experiments	O
correlated	O
PP1	B-GP
activity	O
with	O
pS137	O
-	O
PFN1	B-GP
dephosphorylation	O
,	O
but	O
left	O
uncertain	O
whether	O
the	O
dephosphorylation	O
is	O
carried	O
out	O
directly	O
by	O
PP1	B-GP
,	O
or	O
by	O
an	O
unknown	O
phosphatase	B-GP
whose	O
activity	O
is	O
regulated	O
by	O
PP1	B-GP
.	O

To	O
test	O
this	O
,	O
we	O
transiently	O
expressed	O
Myc	B-GP
-	O
PP1Cα	B-GP
and	O
PFN1	B-GP
in	O
HEK293	O
cells	O
,	O
immunoprecipitated	O
Myc	B-GP
-	O
PP1Cα	B-GP
via	O
an	O
anti	O
-	O
Myc	B-GP
antibody	B-GP
,	O
and	O
tested	O
for	O
co	O
-	O
precipitation	O
of	O
PFN1	B-GP
.	O

Myc	B-GP
-	O
PP2ACα	B-GP
was	O
separately	O
co	O
-	O
expressed	O
with	O
PFN1	B-GP
and	O
immunoprecipitated	O
as	O
a	O
control	O
.	O

We	O
readily	O
detected	O
PFN1	B-GP
in	O
a	O
complex	O
with	O
PP1Cα	B-GP
,	O
but	O
not	O
PP2ACα	B-GP
(	O
Fig	O
.	O
5A	O
).	O

We	O
next	O
tested	O
for	O
preferential	O
binding	O
of	O
PP1Cα	B-GP
to	O
pS137	O
-	O
PFN1	B-GP
vs	O
.	O
unphosphorylated	O
PFN1	B-GP
by	O
using	O
the	O
phosphomimetic	O
PFN1	B-GP
(	O
S137D	O
)	O
vs	O
.	O
phospho	O
-	O
resistant	O
PFN1	B-GP
(	O
S137A	O
)	O
mutant	O
.	O

We	O
transiently	O
expressed	O
HA	B-GP
-	O
tagged	O
PFN1	B-GP
(	O
wt	O
),	O
PFN1	B-GP
(	O
S137A	O
)	O
or	O
PFN1	B-GP
(	O
S137D	O
)	O
in	O
HEK293	O
cells	O
along	O
with	O
Myc	B-GP
-	O
PP1Cα	B-GP
,	O
followed	O
by	O
immunoprecipitation	O
of	O
Myc	B-GP
-	O
PP1Cα	B-GP
and	O
Western	O
blot	O
for	O
co	O
-	O
precipitation	O
of	O
HA	B-GP
-	O
PFN1	B-GP
.	O

PP1Cα	B-GP
bound	O
more	O
phosphomimetic	O
PFN1	B-GP
(	O
S137D	O
)	O
and	O
less	O
phospho	O
-	O
resistant	O
PFN1	B-GP
(	O
S137A	O
)	O
in	O
comparison	O
to	O
PFN1	B-GP
(	O
wt	O
),	O
with	O
all	O
PFN1	B-GP
variants	O
expressed	O
at	O
a	O
similar	O
level	O
(	O
Fig	O
.	O
5B	O
).	O

These	O
data	O
suggested	O
that	O
Ser	O
-	O
137	O
phosphorylation	O
promotes	O
PFN1	B-GP
interaction	O
with	O
PP1	B-GP
,	O
which	O
subsequently	O
dephosphorylates	O
pSer	O
-	O
137	O
.	O

PP1	B-GP
and	O
PFN1	B-GP
interact	O
in	O
cultured	O
cells	O
.	O

A	O
,	O
HEK293	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
an	O
untagged	O
PFN1	B-GP
along	O
with	O
either	O
an	O
empty	O
vector	O
(	O
pcDNA3	O
)	O
(	O
Lane	O
1	O
),	O
or	O
Myc	B-GP
-	O
tagged	O
PP1Cα	B-GP
(	O
Lane	O
2	O
),	O
or	O
PP2ACα	B-GP
(	O
Lane	O
3	O
),	O
followed	O
by	O
immunoprecipitation	O
with	O
an	O
anti	O
-	O
Myc	B-GP
antibody	B-GP
and	O
Western	O
blot	O
for	O
PFN1	B-GP
.	O

PFN1	B-GP
co	O
-	O
immunoprecipitated	O
specifically	O
with	O
PP1Cα	B-GP
,	O
but	O
not	O
PP2ACα	B-GP
.	O
B	O
,	O
HA	B-GP
-	O
PFN1	B-GP
constructs	O
(	O
wt	O
,	O
S137A	O
or	O
S137D	O
)	O
were	O
co	O
-	O
transfected	O
into	O
HEK293	O
cells	O
with	O
pcDNA3	O
(	O
Lanes	O
1	O
–	O
3	O
)	O
or	O
Myc	B-GP
-	O
PP1Cα	B-GP
(	O
Lanes	O
4	O
–	O
6	O
).	O

Myc	B-GP
-	O
PP1Cα	B-GP
was	O
immunoprecipitated	O
with	O
an	O
anti	O
-	O
Myc	B-GP
antibody	B-GP
,	O
and	O
co	O
-	O
immunoprecipitated	O
HA	B-GP
-	O
PFN1	B-GP
was	O
detected	O
by	O
an	O
anti	O
-	O
HA	B-GP
antibody	B-GP
.	O

Relative	O
to	O
PFN1	B-GP
(	O
wt	O
),	O
more	O
PFN1	B-GP
(	O
S137D	O
)	O
and	O
less	O
PFN1	B-GP
(	O
S137A	O
)	O
bound	O
to	O
PP1Cα	B-GP
.	O
C	O
,	O
Purified	O
6His	O
-	O
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
or	O
S137D	O
)	O
proteins	O
were	O
bound	O
to	O
Ni	O
-	O
NTA	O
beads	O
,	O
and	O
subsequently	O
mixed	O
with	O
recombinant	O
PP1Cα	B-GP
(	O
Lanes	O
2	O
–	O
4	O
).	O

Beads	O
without	O
His	O
-	O
PFN1	B-GP
were	O
mixed	O
with	O
the	O
same	O
amount	O
of	O
PP1Cα	B-GP
to	O
control	O
for	O
nonspecific	O
binding	O
(	O
Lane	O
1	O
).	O

Beads	O
were	O
washed	O
,	O
and	O
analyzed	O
for	O
binding	O
of	O
PP1Cα	B-GP
to	O
6His	O
-	O
PFN1	B-GP
by	O
Western	O
blot	O
.	O

6His	O
-	O
PFN1	B-GP
proteins	O
were	O
visualized	O
by	O
Coomassie	O
blue	O
staining	O
.	O

No	O
specific	O
binding	O
was	O
observed	O
between	O
purified	O
PP1Cα	B-GP
and	O
6His	O
-	O
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
or	O
S137D	O
),	O
despite	O
that	O
they	O
were	O
abundantly	O
present	O
.	O

PP1	B-GP
is	O
known	O
to	O
interact	O
directly	O
with	O
a	O
small	O
number	O
of	O
substrates	O
[	O
19	O
].	O

To	O
determine	O
if	O
PP1	B-GP
directly	O
binds	O
PFN1	B-GP
,	O
we	O
tested	O
for	O
their	O
binding	O
in	O
vitro	O
.	O

We	O
immobilized	O
recombinant	O
6His	O
-	O
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
or	O
S137D	O
)	O
proteins	O
on	O
nickel	O
beads	O
,	O
mixed	O
them	O
with	O
bacterially	O
expressed	O
recombinant	O
PP1Cα	B-GP
,	O
and	O
subsequently	O
tested	O
for	O
their	O
interaction	O
via	O
Western	O
blot	O
against	O
PP1Cα	B-GP
.	O

We	O
did	O
not	O
detect	O
any	O
specific	O
binding	O
of	O
PP1Cα	B-GP
to	O
all	O
three	O
forms	O
of	O
6His	O
-	O
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
and	O
S137D	O
),	O
despite	O
that	O
all	O
proteins	O
were	O
abundantly	O
present	O
(	O
Fig	O
.	O
5C	O
).	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
PP1	B-GP
indirectly	O
associates	O
with	O
PFN1	B-GP
through	O
an	O
unknown	O
linker	O
protein	O
,	O
and	O
dephosphorylates	O
pSer	O
-	O
137	O
.	O

Discussion	O

Our	O
prior	O
studies	O
were	O
the	O
first	O
to	O
demonstrate	O
how	O
PFN1	B-GP
'	O
s	O
biological	O
activities	O
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
phosphorylation	O
at	O
Ser	O
-	O
137	O
by	O
the	O
Rho	B-GP
-	I-GP
associated	I-GP
kinase	I-GP
ROCK	B-GP
.	O

Ser	O
-	O
137	O
phosphorylation	O
abolishes	O
PFN1	B-GP
'	O
s	O
binding	O
to	O
polyproline	O
-	O
containing	O
ligands	O
,	O
e	O
.	O
g	O
.	O
huntingtin	B-GP
,	O
which	O
reduces	O
its	O
ability	O
to	O
inhibit	O
polyglutamine	O
-	O
dependent	O
huntingtin	B-GP
aggregation	O
[	O
6	O
].	O

Our	O
current	O
work	O
identifies	O
PP1	B-GP
as	O
the	O
principal	O
phosphatase	B-GP
to	O
dephosphorylate	O
PFN1	B-GP
at	O
Ser	O
-	O
137	O
.	O

By	O
using	O
a	O
phospho	O
-	O
antibody	B-GP
against	O
pSer	O
-	O
137	O
of	O
PFN1	B-GP
,	O
we	O
found	O
that	O
pharmacologic	O
inhibition	O
and	O
genetic	O
knockdown	O
of	O
the	O
catalytic	O
subunit	O
of	O
PP1	B-GP
(	O
PP1Cα	B-GP
),	O
but	O
not	O
PP2A	B-GP
(	O
PP2ACα	B-GP
),	O
increased	O
pS137	O
-	O
PFN1	B-GP
levels	O
in	O
cultured	O
cells	O
.	O

PP1Cα	B-GP
binds	O
PFN1	B-GP
in	O
cultured	O
cells	O
.	O

This	O
interaction	O
increases	O
when	O
Ser	O
-	O
137	O
is	O
mutated	O
to	O
aspartate	O
,	O
mimicking	O
phosphorylation	O
,	O
and	O
decreases	O
when	O
it	O
is	O
mutated	O
to	O
alanine	O
,	O
blocking	O
phosphorylation	O
.	O

The	O
simplest	O
interpretation	O
of	O
our	O
data	O
is	O
that	O
PP1	B-GP
directly	O
dephosphorylates	O
pSer	O
-	O
137	O
of	O
PFN1	B-GP
.	O

PP1	B-GP
is	O
a	O
major	O
eukaryotic	O
serine	B-GP
/	I-GP
threonine	I-GP
phosphatase	I-GP
,	O
and	O
is	O
thought	O
to	O
catalyze	O
the	O
majority	O
of	O
cellular	O
protein	O
dephosphorylation	O
events	O
[	O
19	O
].	O

There	O
are	O
four	O
different	O
catalytic	O
subunits	O
of	O
PP1	B-GP
in	O
mammals	B-OG
(	O
α	O
,	O
β	O
,	O
γ1	O
,	O
γ2	O
),	O
which	O
are	O
associated	O
with	O
a	O
large	O
number	O
of	O
regulatory	O
subunits	O
.	O

This	O
allows	O
for	O
hundreds	O
of	O
dimeric	O
holoenzymes	O
that	O
are	O
highly	O
substrate	O
-	O
specific	O
[	O
19	O
],	O
[	O
20	O
],	O
[	O
21	O
].	O

Our	O
finding	O
that	O
PFN1	B-GP
co	O
-	O
immunoprecipitates	O
with	O
PP1	B-GP
from	O
cultured	O
cells	O
in	O
a	O
phosphorylation	O
-	O
dependent	O
manner	O
suggests	O
that	O
they	O
co	O
-	O
exist	O
in	O
a	O
complex	O
to	O
dephosphorylate	O
pSer	O
-	O
137	O
.	O

However	O
,	O
a	O
lack	O
of	O
direct	O
binding	O
between	O
these	O
two	O
proteins	O
in	O
vitro	O
suggests	O
that	O
they	O
are	O
likely	O
linked	O
in	O
vivo	O
by	O
an	O
unknown	O
PP1	B-GP
-	O
interacting	O
protein	O
(	O
PIP	O
).	O

This	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
PFN1	B-GP
lacks	O
a	O
typical	O
PP1	B-GP
-	O
docking	O
motif	O
(	O
RVxF	O
,	O
SILK	O
or	O
MyPhoNE	O
(	O
myosin	B-GP
phosphatase	I-GP
N	O
-	O
terminal	O
element	O
with	O
the	O
consensus	O
sequence	O
of	O
RxxQV	O
/	O
I	O
/	O
LK	O
/	O
RxY	O
/	O
W	O
))	O
that	O
is	O
found	O
in	O
most	O
PIPs	O
[	O
19	O
].	O

Given	O
the	O
vast	O
number	O
of	O
PIPs	O
estimated	O
to	O
be	O
encoded	O
by	O
the	O
human	B-OG
genome	O
(∼	O
650	O
,	O
180	O
of	O
which	O
are	O
known	O
)	O
[	O
19	O
],	O
identifying	O
the	O
one	O
specifically	O
targeting	O
PP1	B-GP
to	O
PFN1	B-GP
could	O
be	O
a	O
daunting	O
task	O
.	O

However	O
,	O
screening	O
PFN1	B-GP
-	O
binding	O
proteins	O
for	O
this	O
PIP	O
might	O
be	O
a	O
more	O
feasible	O
approach	O
.	O

Our	O
finding	O
that	O
mimicking	O
Ser	O
-	O
137	O
phosphorylation	O
(	O
which	O
should	O
disrupt	O
PFN1	B-GP
'	O
s	O
binding	O
to	O
all	O
polyproline	O
-	O
containing	O
proteins	O
)	O
increases	O
PFN1	B-GP
'	O
s	O
interaction	O
with	O
PP1	B-GP
argues	O
against	O
this	O
PIP	O
being	O
a	O
polyproline	O
-	O
containing	O
ligand	O
of	O
PFN1	B-GP
.	O

This	O
effectively	O
rules	O
out	O
the	O
vast	O
majority	O
of	O
PFN1	B-GP
-	O
interacting	O
proteins	O
as	O
the	O
candidate	O
,	O
and	O
focuses	O
our	O
future	O
efforts	O
on	O
the	O
limited	O
number	O
of	O
non	O
-	O
polyproline	O
ligands	O
of	O
PFN1	B-GP
(	O
e	O
.	O
g	O
.	O
actin	B-GP
and	O
gephyrin	B-GP
)	O
[	O
3	O
].	O

At	O
a	O
minimum	O
,	O
this	O
will	O
reveal	O
the	O
additional	O
linker	O
protein	O
,	O
if	O
existent	O
,	O
between	O
PFN1	B-GP
and	O
the	O
unknown	O
PIP	O
,	O
and	O
take	O
us	O
one	O
step	O
closer	O
to	O
identifying	O
it	O
.	O

As	O
an	O
essential	O
protein	O
for	O
all	O
eukaryotic	O
cells	O
,	O
PFN1	B-GP
has	O
now	O
been	O
linked	O
to	O
several	O
human	B-OG
diseases	O
such	O
as	O
Huntington	B-DS
disease	I-DS
[	O
6	O
]	O
and	O
cancer	B-DS
[	O
7	O
],	O
[	O
8	O
],	O
[	O
9	O
],	O
[	O
10	O
],	O
[	O
11	O
],	O
[	O
12	O
].	O

It	O
will	O
thus	O
be	O
of	O
great	O
interest	O
to	O
identify	O
therapeutic	O
approaches	O
to	O
regulate	O
its	O
activity	O
.	O

Our	O
prior	O
and	O
current	O
identification	O
of	O
ROCK	B-GP
and	O
PP1	B-GP
as	O
direct	O
regulators	O
of	O
Ser	O
-	O
137	O
phosphorylation	O
and	O
dephosphorylation	O
raises	O
the	O
possibility	O
of	O
targeting	O
these	O
two	O
enzymes	O
to	O
manipulate	O
PFN1	B-GP
activity	O
and	O
treat	O
these	O
diseases	O
.	O

For	O
example	O
,	O
ROCK	B-GP
inhibitors	O
(	O
e	O
.	O
g	O
.	O
fasudil	O
),	O
which	O
are	O
expected	O
to	O
up	O
-	O
regulate	O
PFN1	B-GP
activity	O
,	O
are	O
already	O
in	O
clinical	O
use	O
to	O
reduce	O
vasospasm	O
in	O
the	O
setting	O
of	O
subarachnoid	B-DS
hemorrhage	I-DS
[	O
22	O
],	O
[	O
23	O
].	O

Importantly	O
,	O
they	O
ameliorate	O
behavioral	O
deficits	O
of	O
HD	B-DS
transgenic	O
mice	B-OG
[	O
24	O
]	O
and	O
have	O
been	O
validated	O
as	O
being	O
anti	O
-	O
metastatic	O
in	O
several	O
cancer	B-DS
models	O
[	O
25	O
],	O
[	O
26	O
],	O
[	O
27	O
],	O
[	O
28	O
].	O

Our	O
work	O
thus	O
represents	O
an	O
early	O
step	O
in	O
defining	O
the	O
mechanisms	O
by	O
which	O
it	O
may	O
be	O
possible	O
to	O
specifically	O
control	O
PFN1	B-GP
'	O
s	O
activity	O
to	O
benefit	O
patients	O
.	O

Materials	O
and	O
Methods	O

Plasmids	O

Mammalian	O
expression	O
vectors	O
encoding	O
Myc	B-GP
-	O
PP1Cα	B-GP
(	O
wt	O
or	O
H125A	O
)	O
and	O
Myc	B-GP
-	O
PP2ACα	B-GP
were	O
kindly	O
provided	O
by	O
Dr	O
.	O
Hiroshi	O
Shima	O
(	O
Miyagi	O
Cancer	B-DS
Center	O
Research	O
Institute	O
,	O
Japan	O
)	O
[	O
29	O
].	O

Mammalian	O
expression	O
vectors	O
encoding	O
untagged	O
or	O
Myc	B-GP
-	O
tagged	O
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
and	O
S137D	O
)	O
were	O
cloned	O
in	O
pcDNA3	O
as	O
described	O
previously	O
[	O
6	O
].	O

HA	B-GP
-	O
tagged	O
human	B-OG
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
and	O
S137D	O
)	O
was	O
PCR	O
amplified	O
and	O
cloned	O
into	O
the	O
EcoRI	B-GP
(	O
5	O
′)	O
and	O
XhoI	B-GP
(	O
3	O
′)	O
sites	O
of	O
pcDNA3	O
.	O
1	O
.	O

Primer	O
sequences	O
are	O
as	O
follows	O
:	O
5	O
′-	O
CCGGAATTCGCCGCCATGGCCTACCCATATGATGTTCCAGATTACGCTTCTTTGGGTGCCGGGTGGAACGCCTACATCGACAACCTCATG	O
-	O
3	O
′	O
(	O
upper	O
primer	O
containing	O
an	O
HA	B-GP
-	O
tag	O
);	O
5	O
′-	O
CCGCCGCTCGAGTCAGTACTGGGAACGCCGAAGGTGG	O
-	O
3	O
′	O
(	O
lower	O
primer	O
).	O

siRNAs	O
and	O
shRNAs	O

Negative	O
control	O
siRNA	O
(	O
SI03650325	O
)	O
and	O
human	B-OG
PP1Cα	B-GP
-	O
specific	O
siRNA	O
(	O
SI02225748	O
)	O
were	O
purchased	O
from	O
Qiagen	O
.	O

A	O
pool	O
of	O
three	O
siRNAs	O
targeting	O
different	O
regions	O
of	O
human	B-OG
PP2ACα	B-GP
were	O
purchased	O
from	O
Santa	O
Cruz	O
(	O
sc	O
-	O
43509	O
).	O

To	O
silence	O
PFN1	B-GP
,	O
a	O
21nt	O
sequence	O
(	O
5	O
′-	O
GGAATTTAGCATGGATCTTCG	O
-	O
3	O
′)	O
was	O
custom	O
-	O
designed	O
to	O
target	O
246	O
-	O
267nt	O
of	O
human	B-OG
PFN1	B-GP
mRNA	O
,	O
and	O
cloned	O
as	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
downstream	O
of	O
the	O
U6	O
promoter	O
in	O
a	O
lentiviral	O
vector	O
,	O
pFLRu	O
-	O
FH	O
(	O
kind	O
gift	O
of	O
Dr	O
.	O
Greg	O
Longmore	O
)	O
[	O
30	O
].	O

A	O
control	O
shRNA	O
was	O
similarly	O
constructed	O
using	O
a	O
non	O
-	O
targeting	O
sequence	O
(	O
5	O
′-	O
CAACAAGATGAAGAGCACCAA	O
-	O
3	O
′)	O
adapted	O
from	O
the	O
MISSION	O
Non	O
-	O
Target	O
shRNA	O
control	O
vector	O
from	O
Sigma	O
.	O

Lentiviral	O
particles	O
were	O
purified	O
by	O
the	O
Hope	O
Center	O
Viral	O
Vectors	O
Core	O
at	O
Washington	O
University	O
.	O

Antibodies	B-GP

Commercially	O
available	O
primary	O
antibodies	B-GP
were	O
as	O
follows	O
:	O
rabbit	B-OG
anti	O
-	O
PFN1	B-GP
(	O
Cell	O
Signaling	O
,	O
#	O
3237	O
),	O
mouse	B-OG
anti	O
-	O
Myc	B-GP
tag	O
(	O
Santa	O
Cruz	O
,	O
sc	O
-	O
40	O
),	O
rabbit	B-OG
anti	O
-	O
actin	B-GP
(	O
Santa	O
Cruz	O
,	O
sc	O
-	O
1616	O
-	O
R	O
),	O
rabbit	B-OG
anti	O
-	O
PP1Cα	B-GP
(	O
Cell	O
Signaling	O
,	O
#	O
2582	O
),	O
rabbit	B-OG
anti	O
-	O
PP2ACα	B-GP
(	O
Cell	O
Signaling	O
,	O
#	O
2038	O
),	O
mouse	B-OG
anti	O
-	O
HA	B-GP
tag	O
(	O
Covance	O
,	O
MMS	O
-	O
101P	O
).	O

Custom	O
-	O
made	O
antibodies	B-GP
include	O
rabbit	B-OG
polyclonal	O
antibody	B-GP
against	O
the	O
C	O
-	O
terminus	O
of	O
PFN1	B-GP
(	O
KCYEMASHLRRSQY	O
,	O
gift	O
of	O
Dr	O
.	O
Nicholas	O
A	O
.	O

DiProspero	O
)	O
and	O
affinity	O
purified	O
rabbit	B-OG
polyclonal	O
anti	O
-	O
pS137	O
-	O
PFN1	B-GP
(	O
New	O
England	O
Peptides	O
,	O
Ac	O
-	O
CMASHLRR	O
(	O
pS	O
)	O
QY	O
-	O
OH	O
)	O
[	O
6	O
].	O

Secondary	O
antibodies	B-GP
used	O
for	O
Western	O
blotting	O
include	O
alkaline	B-GP
phosphatase	I-GP
-	O
conjugated	O
secondary	O
antibodies	B-GP
(	O
Sigma	O
,	O
A3562	O
)	O
and	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
secondary	O
antibodies	B-GP
(	O
Amersham	O
Biosciences	O
,	O
NA9340V	O
for	O
anti	O
-	O
rabbit	B-OG
and	O
NA931V	O
for	O
anti	O
-	O
mouse	B-OG
antibodies	B-GP
).	O

Secondary	O
antibodies	B-GP
for	O
immunofluorescence	O
staining	O
include	O
Alexa	O
Fluor	O
®	O
488	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
IgG	B-GP
(	O
Invitrogen	O
,	O
A	O
-	O
11034	O
)	O
and	O
Alexa	O
Fluor	O
®	O
546	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
mouse	B-OG
IgG	B-GP
(	O
Invitrogen	O
,	O
A	O
-	O
11030	O
).	O

Agarose	O
conjugated	O
with	O
secondary	O
anti	O
-	O
mouse	B-OG
IgG	B-GP
(	O
A6531	O
)	O
and	O
EZview	O
Red	O
affinity	O
gel	O
conjugated	O
with	O
rabbit	B-OG
anti	O
-	O
c	B-GP
-	I-GP
Myc	I-GP
antibody	B-GP
(	O
E6654	O
)	O
were	O
purchased	O
from	O
Sigma	O
.	O

Reagents	O

Alpha	O
isoform	O
of	O
bacterially	O
expressed	O
recombinant	O
PP1	B-GP
catalytic	O
subunit	O
was	O
purchase	O
from	O
Sigma	O
(	O
P7937	O
).	O

Nickel	O
-	O
NTA	O
beads	O
were	O
purchased	O
from	O
Qiagen	O
(	O
30410	O
).	O

Protease	B-GP
inhibitor	O
cocktail	O
(	O
11	O
-	O
836	O
-	O
170	O
-	O
001	O
)	O
was	O
purchased	O
from	O
Roche	O
Diagnostics	O
.	O

ECL	O
Plus	O
Western	O
blotting	O
detection	O
kit	O
(	O
RPN2132	O
)	O
was	O
purchased	O
from	O
GE	O
Healthcare	O
.	O

Lysophosphatidic	O
acid	O
(	O
L7260	O
)	O
was	O
purchased	O
from	O
Sigma	O
.	O

Okadaic	O
acid	O
(	O
495609	O
),	O
Endothall	O
(	O
324760	O
),	O
Fostriecin	O
(	O
344280	O
)	O
and	O
Hydroxyfasudil	O
(	O
390602	O
)	O
were	O
purchased	O
from	O
Calbiochem	O
.	O

Fetal	O
bovine	O
serum	O
(	O
SH3007103	O
)	O
was	O
purchased	O
from	O
Hyclone	O
.	O

Gold	O
anti	O
-	O
fade	O
mounting	O
media	O
was	O
purchased	O
from	O
Invitrogen	O
(	O
P36934	O
).	O

Cell	O
culture	O
and	O
transfection	O

HEK293	O
,	O
HeLa	O
and	O
NIH	O
3T3	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
penicillin	O
/	O
streptomycin	O
.	O

Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
was	O
used	O
for	O
transfecting	O
both	O
DNAs	O
and	O
siRNAs	O
using	O
the	O
protocol	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Immunoprecipitation	O

HEK293	O
cells	O
over	O
-	O
expressing	O
Myc	B-GP
-	O
PP1Cα	B-GP
(	O
wt	O
or	O
H125A	O
)	O
or	O
Myc	B-GP
-	O
PP2ACα	B-GP
were	O
lysed	O
with	O
buffer	O
containing	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
),	O
150	O
mM	O
NaCl	O
,	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
and	O
protease	B-GP
inhibitors	O
.	O

Cleared	O
lysate	O
was	O
mixed	O
with	O
agarose	O
beads	O
bound	O
with	O
anti	O
-	O
Myc	B-GP
antibody	B-GP
.	O

After	O
2	O
hr	O
of	O
mixing	O
at	O
4	O
°	O
C	O
,	O
beads	O
were	O
washed	O
4	O
times	O
with	O
lysis	O
buffer	O
,	O
and	O
analyzed	O
by	O
Western	O
blot	O
for	O
co	O
-	O
immunoprecitation	O
of	O
untagged	O
or	O
HA	B-GP
-	O
tagged	O
PFN1	B-GP
via	O
antibodies	B-GP
against	O
PFN1	B-GP
(	O
1	O
∶	O
1000	O
)	O
or	O
the	O
HA	B-GP
tag	O
(	O
1	O
∶	O
1000	O
).	O

For	O
in	O
vitro	O
pull	O
-	O
down	O
experiment	O
,	O
20	O
µl	O
nickel	O
NTA	O
beads	O
were	O
pre	O
-	O
blocked	O
with	O
1	O
%	O
bovine	O
serum	O
albumin	B-GP
(	O
BSA	B-GP
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
,	O
and	O
subsequently	O
mixed	O
with	O
10	O
µg	O
6His	O
-	O
tagged	O
PFN1	B-GP
(	O
wt	O
,	O
S137A	O
and	O
S137D	O
)	O
proteins	O
previously	O
purified	O
from	O
bacteria	B-OG
[	O
6	O
]	O
for	O
30	O
min	O
at	O
4	O
°	O
C	O
.	O

After	O
washing	O
,	O
2	O
µg	O
of	O
recombinant	O
PP1Cα	B-GP
was	O
added	O
to	O
the	O
beads	O
in	O
100	O
µl	O
binding	O
buffer	O
containing	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
),	O
150	O
mM	O
NaCl	O
,	O
0	O
.	O
1	O
%	O
BSA	B-GP
,	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
and	O
protease	B-GP
inhibitors	O
.	O

Following	O
1	O
hr	O
incubation	O
at	O
4	O
°	O
C	O
,	O
beads	O
were	O
washed	O
4	O
times	O
with	O
binding	O
buffer	O
without	O
BSA	B-GP
,	O
and	O
analyzed	O
by	O
Western	O
blot	O
for	O
PP1Cα	B-GP
or	O
Coomassie	O
blue	O
staining	O
for	O
6His	O
-	O
PFN1	B-GP
.	O

Immunofluorescence	O
staining	O

Cultured	O
cells	O
were	O
fixed	O
for	O
30	O
min	O
with	O
4	O
%	O
paraformaldehyde	O
,	O
washed	O
3	O
times	O
with	O
PBS	O
,	O
followed	O
by	O
blocking	O
with	O
2	O
%	O
BSA	B-GP
in	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
for	O
30	O
min	O
.	O

P3490	O
antibody	B-GP
was	O
diluted	O
at	O
1	O
∶	O
5000	O
(	O
v	O
/	O
v	O
)	O
with	O
blocking	O
buffer	O
and	O
incubated	O
with	O
cells	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
or	O
overnight	O
at	O
4	O
°	O
C	O
.	O

Cells	O
were	O
washed	O
4	O
times	O
with	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
incubated	O
with	O
1	O
∶	O
500	O
dilution	O
of	O
Alexa	O
Fluor	O
®	O
488	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
secondary	O
antibody	B-GP
in	O
blocking	O
buffer	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
,	O
washed	O
4	O
times	O
with	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
and	O
mounted	O
.	O

For	O
total	O
PFN1	B-GP
staining	O
,	O
custom	O
-	O
made	O
rabbit	B-OG
polyclonal	O
antibody	B-GP
against	O
the	O
C	O
-	O
terminus	O
of	O
PFN1	B-GP
(	O
KCYEMASHLRRSQY	O
)	O
was	O
used	O
at	O
1	O
∶	O
100	O
and	O
followed	O
by	O
secondary	O
antibody	B-GP
incubation	O
as	O
for	O
P3490	O
.	O

For	O
double	O
labeling	O
,	O
cells	O
were	O
simultaneously	O
incubated	O
with	O
P3490	O
(	O
1	O
∶	O
5000	O
)	O
and	O
anti	O
-	O
Myc	B-GP
antibody	B-GP
(	O
1	O
∶	O
1000	O
)	O
overnight	O
at	O
4	O
°	O
C	O
,	O
followed	O
by	O
2	O
hr	O
incubation	O
with	O
1	O
∶	O
500	O
dilution	O
of	O
Alexa	O
Fluor	O
®	O
488	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
antibody	B-GP
and	O
Alexa	O
Fluor	O
®	O
546	O
goat	B-OG
anti	O
-	O
mouse	B-OG
antibodies	B-GP
at	O
room	O
temperature	O
.	O

In	O
all	O
cases	O
,	O
DAPI	O
was	O
included	O
in	O
the	O
secondary	O
antibody	B-GP
solution	O
at	O
a	O
concentration	O
of	O
1	O
µg	O
/	O
ml	O
.	O

Images	O
were	O
acquired	O
using	O
the	O
Zeiss	O
LSM	O
5	O
PASCAL	O
system	O
equipped	O
with	O
the	O
following	O
lasers	O
:	O
405	O
nm	O
,	O
488	O
nm	O
,	O
543	O
nm	O
.	O

For	O
quantitative	O
immunostaining	O
within	O
96	O
-	O
well	O
plates	O
,	O
HEK293	O
cells	O
were	O
grown	O
to	O
approximately	O
90	O
%	O
confluence	O
,	O
fixed	O
,	O
blocked	O
,	O
stained	O
with	O
P3490	O
(	O
1	O
∶	O
5000	O
)	O
or	O
anti	O
-	O
PFN1	B-GP
antibody	B-GP
(	O
1	O
∶	O
100	O
)	O
and	O
Alexa	O
Fluor	O
®	O
488	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
antibody	B-GP
(	O
1	O
∶	O
500	O
),	O
and	O
counterstained	O
with	O
DAPI	O
as	O
described	O
above	O
.	O

Cells	O
were	O
washed	O
4	O
times	O
with	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
left	O
in	O
150	O
µl	O
PBS	O
,	O
and	O
quantified	O
for	O
fluorescence	O
intensity	O
(	O
490	O
/	O
519	O
nm	O
for	O
Alexa	O
Fluor	O
®	O
488	O
and	O
365	O
/	O
439	O
nm	O
for	O
DAPI	O
)	O
using	O
a	O
fluorescence	O
plate	O
reader	O
(	O
INFINITE	O
M1000	O
,	O
Tecan	O
,	O
Inc	O
).	O

Background	O
fluorescence	O
was	O
acquired	O
using	O
cells	O
stained	O
only	O
with	O
the	O
secondary	O
antibody	B-GP
.	O

Background	O
subtracted	O
fluorescence	O
intensity	O
for	O
Alexa	O
Fluor	O
®	O
488	O
,	O
which	O
represented	O
P3490	O
reactivity	O
,	O
was	O
then	O
normalized	O
against	O
DAPI	O
level	O
to	O
control	O
for	O
total	O
cell	O
number	O
.	O

For	O
all	O
experiments	O
,	O
at	O
least	O
4	O
replicate	O
wells	O
were	O
quantified	O
for	O
a	O
given	O
condition	O
,	O
and	O
each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
independently	O
.	O

Antigen	O
competition	O

P3490	O
was	O
first	O
diluted	O
1	O
∶	O
5000	O
in	O
the	O
blocking	O
buffers	O
for	O
immunofluorescence	O
(	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
/	O
2	O
%	O
BSA	B-GP
)	O
or	O
Western	O
blot	O
(	O
TBS	O
/	O
0	O
.	O
05	O
%	O
Tween	O
20	O
/	O
5	O
%	O
skim	O
milk	O
),	O
and	O
then	O
mixed	O
at	O
1	O
∶	O
200	O
molar	O
ratio	O
(	O
antibody	B-GP
/	O
peptide	O
)	O
with	O
PFN1	B-GP
peptides	O
containing	O
(	O
Ac	O
-	O
CMASHLRR	O
(	O
pS	O
)	O
QY	O
-	O
OH	O
)	O
or	O
lacking	O
a	O
phosphate	O
on	O
Ser	O
-	O
137	O
(	O
Ac	O
-	O
CMASHLRRSQY	O
-	O
OH	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

A	O
control	O
antibody	B-GP
solution	O
was	O
set	O
up	O
by	O
mixing	O
an	O
equivalent	O
volume	O
of	O
water	O
(	O
instead	O
of	O
peptides	O
)	O
with	O
P3490	O
.	O

All	O
antibody	B-GP
solutions	O
(	O
no	O
peptide	O
,	O
S137	O
-	O
peptide	O
and	O
pS137	O
-	O
peptide	O
)	O
were	O
subsequently	O
used	O
to	O
immunostain	O
or	O
immunoblot	O
HEK293	O
cells	O
as	O
described	O
above	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

